Sign In
Buy RZLT
$4.58
+0.580 (+14.50%)
At Close: Jun 03, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
07:30am, Thursday, 04'th Jun 2026
REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypo
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
12:31pm, Tuesday, 02'nd Jun 2026
Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enr
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
07:00am, Tuesday, 02'nd Jun 2026
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th May 2026
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by
Rezolute to Participate in Upcoming Investor Conferences
07:00am, Monday, 11'th May 2026
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared t
Rezolute, Inc. Investigated by the Portnoy Law Firm
09:00am, Friday, 24'th Apr 2026
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
11:10am, Wednesday, 25'th Mar 2026
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question
02:00pm, Tuesday, 24'th Mar 2026
In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
07:00am, Tuesday, 24'th Mar 2026
REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused
Reviewing Rezolute (NASDAQ:RZLT) & ADMA Biologics (NASDAQ:ADMA)
02:06am, Monday, 09'th Mar 2026
ADMA Biologics (NASDAQ: ADMA - Get Free Report) and Rezolute (NASDAQ: RZLT - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based o
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute
09:23am, Friday, 06'th Mar 2026
NEW YORK--(BUSINESS WIRE)---- $RZLT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Compa
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)
09:47am, Thursday, 05'th Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffer
Rezolute to Participate in the Citizens Life Sciences Conference
07:00am, Wednesday, 04'th Mar 2026
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused
